pentobarbital will lower the level or influence of lumacaftor/ivacaftor by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Steer clear of; coadministration with CYP3A inducers may perhaps end in reduced plasma concentrations of elvitegravir and/or maybe a concomitantly adm